New dengue drug could cut fever time and virus levels

NCT ID NCT06006559

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This Phase 2 trial tests an experimental drug called EYU688 in 108 adults with dengue fever. Participants receive either the drug or a placebo to see if it lowers the amount of virus in the blood and shortens fever. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EYU688
What this could lead to: If it works, this could lead to a new treatment that shortens dengue fever and reduces the amount of virus in the blood.
What could go wrong: This is an early Phase 2 trial with only 108 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DENGUE

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Manaus, Amazonas, 69040-000, Brazil
Novartis Investigative Site
RECRUITING

Brasília, Federal District, 71635-580, Brazil
Novartis Investigative Site
RECRUITING

Rio de Janeiro, Rio de Janeiro, 21040-360, Brazil
Novartis Investigative Site
RECRUITING

Rio Grande, Rio Grande do Sul, 90035-001, Brazil
Novartis Investigative Site
RECRUITING

Sorocaba, São Paulo, 18040-425, Brazil
Novartis Investigative Site
RECRUITING

Sao Jose Rio Preto, 15090 000, Brazil
Novartis Investigative Site
WITHDRAWN

Barranquilla, Atlántico, 080012, Colombia
Novartis Investigative Site
WITHDRAWN

Bucaramanga, Santander Department, 681017, Colombia
Novartis Investigative Site
RECRUITING

Cali, Valle del Cauca Department, 760032, Colombia
Novartis Investigative Site
RECRUITING

Belagavi, Karnataka, 590010, India
Novartis Investigative Site
WITHDRAWN

Mumbai, Maharashtra, 400008, India
Novartis Investigative Site
RECRUITING

Pune, Maharashtra, 411013, India
Novartis Investigative Site
RECRUITING

Jaipur, Rajasthan, 302017, India
Novartis Investigative Site
RECRUITING

Chennai, Tamil Nadu, 600113, India
Novartis Investigative Site
RECRUITING

Kuantan, Pahang, 25200, Malaysia
Novartis Investigative Site
RECRUITING

Ipoh, Perak, 30450, Malaysia
Novartis Investigative Site
RECRUITING

Seberang Jaya, Pulau Pinang, 13700, Malaysia
Novartis Investigative Site
RECRUITING

Miri, Sarawak, 98000, Malaysia
Novartis Investigative Site
RECRUITING

Kuala Selangor, 68000, Malaysia
Novartis Investigative Site
RECRUITING

Singapore, Singapore, S308433, Singapore
Novartis Investigative Site
RECRUITING

Singapore, 169608, Singapore
Novartis Investigative Site
RECRUITING

Haiphong, 180000, Vietnam
Novartis Investigative Site
RECRUITING

Hanoi, 100000, Vietnam
Novartis Investigative Site
RECRUITING

Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.